Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $33.00.

Several research firms have weighed in on AVTX. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. Stifel Nicolaus assumed coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $36.00 target price for the company. Jefferies Financial Group began coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $23.00 price objective for the company. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Finally, Wedbush reissued an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday, March 20th.

Avalo Therapeutics Trading Down 4.8 %

NASDAQ AVTX opened at $4.41 on Friday. The company has a 50 day moving average price of $6.90 and a two-hundred day moving average price of $8.71. Avalo Therapeutics has a 12-month low of $4.31 and a 12-month high of $17.49.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the period. Marshall Wace LLP bought a new position in Avalo Therapeutics during the 4th quarter worth about $114,000. Walleye Capital LLC acquired a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $145,000. Northern Trust Corp bought a new stake in shares of Avalo Therapeutics in the fourth quarter valued at about $168,000. Finally, Bank of Montreal Can acquired a new position in shares of Avalo Therapeutics during the fourth quarter worth about $446,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.